Shots: Pfizer launched a pilot program to support the state’s planning, deployment & administration of the COVID-19 vaccine candidate, to build on coordination with the relevant US agencies Pfizer has […]readmore
Tags : Program
Shots: The company will not expand the P-II EMERGE study that assesses Vopratelimab + ipilimumab in PD-(L)1 inhibitor experienced NSCLC patient. Early evaluation of the study showed that the trial […]readmore
Shots: The companies will partner to promote Lyumjev (insulin lispro-aabc injection, 100 & 200 units/mL) with Dexcom G6 CGM to aid HCPs in the US for the management of diabetes, […]readmore
Shots: Lannett has provided an update on the clinical advancement of its biosimilar Insulin glargine. Following FDA meeting, Lannett has received FDA’s positive feedback on the clinical and CMC advancement […]readmore
Shots: The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9,000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca, FibroGen and Astellas […]readmore
Shots: The program has two parts Growth Track, in which companies will receive €75 funding for co-creating solutions, as well as co-working space at Bayer’s Pharmaceuticals division headquarters in Berlin, […]readmore
Shots: Black Belt to get $5.64M (€5M) upfront, equity investment of $2.26M (€2M), milestones and royalties on sales. CASI to get exclusive WW rights to develop and commercialize Black Belt’s […]readmore
Shots: Xencor to receive an upfront, development, regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for […]readmore
Shots: Roche & Vaccibody collaborated to assess the combination of VB10.16 + Tecentriq in P-II, for 50 patients with advanced cervical cancer to evaluate its safety, tolerability, immunogenicity and efficacy […]readmore
Shots: Repare to receive $15M upfront, $160M milestones and royalties on sales of product from ONO. Repare to get exclusive development and commercialization rights for Repare’s Polθ Inhibitor Program in […]readmore